Artificial Intelligence in Genomics Market Size, Share, and Trends

Artificial Intelligence in Genomics Market (By Offering: Software, Services; By Application: Drug Discovery & Development, Precision Medicine, Diagnostics, Animal Research and Agriculture, Others; By End User: Pharmaceutical & Biotech Companies, Government Organizations, Research Organizations, Others; By Technology: Machine Learning, Other Technologies; By Functionality) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2024 - 2033

  • Last Updated : May 2024
  • Report Code : 1721
  • Category : Healthcare

AI in Genomics Market Size and Growth

The global artificial intelligence in genomics market size was valued at USD 560 million in 2023 and it is expected to hit around USD 16,431.16 million by 2033, poised to grow at a CAGR of 40.2% from 2024 to 2033.

Artificial Intelligence in Genomics Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Artificial Intelligence in Genomics Market Key Takeaways

  • North America held a market share of 29.25% in 2023.
  • By application, the drug discovery & development segment registered the maximum market share in 2023.
  • By end user, the pharmaceutical and biotech companies segment is expected to capture the biggest revenue share in 2023.

Artificial Intelligence in Genomics Market Size in the U.S. 2024 to 2033

The U.S. artificial intelligence in genomics market size was estimated at USD 114.88 million in 2023 and is predicted to be worth around USD 3,583.23 million by 2033, at a CAGR of 41.1% from 2024 to 2033.

U.S. Artificial Intelligence in Genomics Market Size 2024 to 2033

Based on the region, North America dominated the global AI in genomics market in 2023. North America is the home to several leading pharmaceutical and biotechnology companies that has significantly contributed to the growth of the AI in genomics market. The huge investments in the adoption of AI technology in the pharma sector of North America has led to the huge market growth. Further, the presence of huge patient population owing to the presence of high geriatric population and increased prevalence of chronic diseases has resulted in the huge adoption of the AI-based technology in the healthcare sector. It is estimated that more than half of the US population is suffering from one or more chronic diseases. Moreover, by 2060, about 24% of the US population would be of age 65 years or above. Thus the rising demand for innovative medicines and quick treatment services is expected to boost the growth of the North America AI in genomics market.

Asia Pacific is expected to be the fastest-growing market during the forecast period. The surging uses of AI across various application such as agriculture, animal research, diagnostics, and drug discovery is driving the market growth significantly. Moreover, the presence of several top research organizations in the region and rising demand for the AI technology among them is fostering the growth of the AI in genomics market in Asia Pacific region.

Artificial Intelligence in Genomics Market Share, By Region, 2023 (%)

Artificial Intelligence in Genomics Market Size in Europe 2023 to 2033

The Europe artificial intelligence in genomics market size was calculated at USD 141.85 million in 2023 and is projected to expand around USD 4,436.41 million by 2033, poised to grow at a CAGR of 41.1% from 2024 to 2033.

Year Market Size (USD Million)
2023 141.85
2024 200.18
2025 282.49
2026 398.63
2027 562.50
2028 793.69
2029 1,119.85
2030 1,579.99
2031 2,229.10
2032 3,144.77
2033 4,436.41

 

Artificial Intelligence in Genomics Market Growth Factors

The rising investments by the pharmaceutical companies in the drug discovery and drug development activities is expected to boost the demand for the artificial intelligence in genomics market during the forecast period. The costs associated with the drug discovery and drug development is extremely high and hence there is a rapidly rising need to control the costs of these activities. The introduction of artificial intelligence technology in the genomics field is expected to enhance the operations, improve quality, and decrease costs. The growing adoption of the AI in the precision medicine is significantly driving the growth of the AI in genomics market.

Drug discovery is a costly and time consuming activity. The in-vivo and in-vitro methods used in the drug discovery is time consuming and very costly. Therefore, the demand for the AI is expected to rise significantly in the forthcoming future in the genomics industry. Drug discovery and drug development involves extensive research and collecting data, storing data, and meaningful interpretation of data, which involves a lot of time. Data storage and analytics is also very expensive. After this, the drug development and clinical trials are conducted, which further involves a huge cost.

Moreover, the selection, deployments, and retention of candidates is a complex and expensive task. With the adoption of AI in genomics, most of the tasks such as data collection, analytics, data storage and data filtration, and many more activities are automated and the quality of the work improves. Further, the growing prevalence of various chronic and infectious diseases among the population is significantly boosting the growth of the pharmaceutical companies and thereby it attracts a huge investments towards the drug discovery and drug development activities. This is expected to significantly drive the growth of the global AI in genomics market in the upcoming future.

Artificial Intelligence in Genomics Market Scope

Report Coverage Details
Market Size in 2023 USD 560 Million
Market Size by 2033 USD 16,431.16 Million
Growth Rate from 2024 to 2033 CAGR of 40.2%
Largest Market North America 
Fastest Growing Market  Asia Pacific 
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Offering, By Application, By End User, By Technology, and By Functionality
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Offering Insights

Based on the offering, the software segment dominated the global AI in genomics market in 2023. This growth is attributed to the increased adoption of the AI-based software in the research and development phase of the drug discovery and drug development activities. Moreover, the presence of several number of leading pharmaceutical companies along with the numerous contract research organization and the higher adoption of software for collecting, storing, and analyzing data has led to the growth of the software segment in the global AI in genomics market. The rising number of contract research organizations, biotech companies, and healthcare providers coupled with the rising adoption of the AI technology is expected to have a significant and positive impact on the growth of the software segment in the forthcoming years.

On the other hand, the services is expected to be the fastest-growing segment during the forecast period. The lack of availability of the AI skilled workers is a major factor behind the rising demand for the services in the market. The operation of AI-based systems needs special skills and understanding of this latest technology and hence the demand for services is expected to grow significantly during the forecast period.

Application Insights

Based on the application, the drug discovery & development segment dominated the global AI in genomics market in 2023. The rising prevalence of various chronic, infectious, and gene related diseases among the global population is significantly attracting investments towards the drug discovery & development activities. The rising need to control costs and enhance efficiency and provide desired results, the adoption of the AI in genomics significantly fostered in the past decade. Drug discovery and development became the highest adopter of the AI technology in the genomics industry. Moreover, the growing government and corporate efforts to decrease the healthcare costs has resulted in the adoption of the AI in the drug discovery and development activity.

The precision medicine is expected to be the most opportunistic segment during the forecast period. The rising advances in the oncology and cancer biologics is driving the growth of the precision medicine segment. The rising adoption of AI in the precision medicine in the prevention and management of cancer is expected to significantly drive the growth of the precision medicine segment in the global AI in genomics market.

End User Insights

Based on the end user, the pharmaceutical and biotech companies segment dominated the global AI in genomics market in 2023. The presence of the leading pharmaceutical companies across the globe is significantly driving the demand for the AI technology for various activities like making precision medicine, drug discovery, drug development, and manufacturing of diagnostic devices using AI technology. Further, the rapidly growing biotechnology companies across the globe is significantly responsible for the growth of the AI in genomics market owing to its rising adoption of the AI technology.

Healthcare providers is expected to be the fastest-growing segment during the forecast period. The growing geriatric population and rising prevalence of diseases is significantly boosting the number of hospital admissions. The healthcare providers are under immense pressure to provide quick and enhanced services to the patients at low cost. Therefore, the healthcare sector is significantly investing in the adoption of the AI-based services and software to reduce healthcare costs, improve care quality, and provide quick treatment services to the patients.

Artificial Intelligence in Genomics Market Recent Developments

  • In February 2020, IBM Watson Health partnered with the Harvard and Broad Institute of MIT to explore and analyze genomics data to understand the intrinsic susceptibility.

AI in Genomics Market Companies

  • IBM
  • NVIDIA Corporation
  • Benevolent AI
  • Verge Genomics
  • MolecularMatch, Inc.
  • SOPHiA GENETICS
  • PrecisionLife Ltd.
  • Lifebit
  • FDNA, Inc.
  • Empiric Logic
  • Microsoft
  • Deep Genomics
  • Fabric Genomics Inc.
  • Freenome Holdings, Inc.
  • Cambridge Cancer Genomics
  • Data4Cure Inc.
  • Engine Biosciences Pte. Ltd.
  • Genoox Ltd.
  • Diploid
  • DNAnexus Inc.

Segments Covered in the Report

By Offering

  • Software
  • Services

By Application

  • Drug Discovery & Development
  • Precision Medicine
  • Diagnostics
  • Animal Research and Agriculture
  • Others

By End User

  • Pharmaceutical & Biotech Companies
  • Government Organizations
  • Research Organizations
  • Others

By Technology

  • Machine Learning
    • Deep Learning
    • Supervised Learning
    • Reinforcement Learning
    • Unsupervised Learning
    • Other
  • Other Technologies

By Functionality

  • Genome Sequencing
  • Gene Editing
  • Clinical Workflows
  • Predictive Genetic Testing & Preventive Medicine

 By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

The global artificial intelligence in genomics market size was reached at USD 560 million in 2023 and it is projected to rake around USD 16,431.16 million by 2033.

The global artificial intelligence in genomics market is expected to drive growth at a CAGR of 40.2% over the forecast period 2024 to 2033.

The major players operating in the artificial intelligence in genomics market are IBM, NVIDIA Corporation, Benevolent AI, Verge Genomics, MolecularMatch, Inc., SOPHiA, ENETICS, PrecisionLife Ltd., Lifebit, FDNA, Inc., Empiric Logic, Microsoft, Deep Genomics, Fabric Genomics Inc., Freenome Holdings, Inc., Cambridge Cancer Genomics, Data4Cure Inc., Engine Biosciences Pte. Ltd., Genoox Ltd., Diploid, DNAnexus Inc.

The growing adoption of the AI in the precision medicine is significantly driving the growth of the AI in genomics market.

North America region will lead the global artificial intelligence in genomics market over the forecast period 2024 to 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Artificial Intelligence in Genomics Market 

5.1. COVID-19 Landscape: Artificial Intelligence in Genomics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Artificial Intelligence in Genomics Market, By Offering

8.1. Artificial Intelligence in Genomics Market, by Offering, 2024-2033

8.1.1. Software

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Services

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Artificial Intelligence in Genomics Market, By Application

9.1. Artificial Intelligence in Genomics Market, by Application, 2024-2033

9.1.1. Drug Discovery & Development

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Precision Medicine

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Diagnostics

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Animal Research and Agriculture

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Artificial Intelligence in Genomics Market, By End User 

10.1. Artificial Intelligence in Genomics Market, by End User, 2024-2033

10.1.1. Pharmaceutical & Biotech Companies

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Government Organizations

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Research Organizations

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Artificial Intelligence in Genomics Market, By Technology

11.1. Artificial Intelligence in Genomics Market, by Technology, 2024-2033

11.1.1. Machine Learning

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Other Technologies

11.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Artificial Intelligence in Genomics Market, By Functionality

12.1. Artificial Intelligence in Genomics Market, by Functionality, 2024-2033

12.1.1. Genome Sequencing

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Gene Editing

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Clinical Workflows

12.1.3.1. Market Revenue and Forecast (2021-2033)

12.1.4. Predictive Genetic Testing & Preventive Medicine

12.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Artificial Intelligence in Genomics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Offering (2021-2033)

13.1.2. Market Revenue and Forecast, by Application (2021-2033)

13.1.3. Market Revenue and Forecast, by End User (2021-2033)

13.1.4. Market Revenue and Forecast, by Technology (2021-2033)

13.1.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Offering (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Application (2021-2033)

13.1.6.3. Market Revenue and Forecast, by End User (2021-2033)

13.1.6.4. Market Revenue and Forecast, by Technology (2021-2033)

13.1.7. Market Revenue and Forecast, by Functionality (2021-2033) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Offering (2021-2033)

13.1.8.2. Market Revenue and Forecast, by Application (2021-2033)

13.1.8.3. Market Revenue and Forecast, by End User (2021-2033)

13.1.8.4. Market Revenue and Forecast, by Technology (2021-2033)

13.1.8.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Offering (2021-2033)

13.2.2. Market Revenue and Forecast, by Application (2021-2033)

13.2.3. Market Revenue and Forecast, by End User (2021-2033)

13.2.4. Market Revenue and Forecast, by Technology (2021-2033) 

13.2.5. Market Revenue and Forecast, by Functionality (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Offering (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

13.2.6.3. Market Revenue and Forecast, by End User (2021-2033)

13.2.7. Market Revenue and Forecast, by Technology (2021-2033) 

13.2.8. Market Revenue and Forecast, by Functionality (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Offering (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Application (2021-2033)

13.2.9.3. Market Revenue and Forecast, by End User (2021-2033)

13.2.10. Market Revenue and Forecast, by Technology (2021-2033)

13.2.11. Market Revenue and Forecast, by Functionality (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Offering (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Application (2021-2033)

13.2.12.3. Market Revenue and Forecast, by End User (2021-2033)

13.2.12.4. Market Revenue and Forecast, by Technology (2021-2033)

13.2.13. Market Revenue and Forecast, by Functionality (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Offering (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Application (2021-2033)

13.2.14.3. Market Revenue and Forecast, by End User (2021-2033)

13.2.14.4. Market Revenue and Forecast, by Technology (2021-2033)

13.2.15. Market Revenue and Forecast, by Functionality (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Offering (2021-2033)

13.3.2. Market Revenue and Forecast, by Application (2021-2033)

13.3.3. Market Revenue and Forecast, by End User (2021-2033)

13.3.4. Market Revenue and Forecast, by Technology (2021-2033)

13.3.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Offering (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

13.3.6.3. Market Revenue and Forecast, by End User (2021-2033)

13.3.6.4. Market Revenue and Forecast, by Technology (2021-2033)

13.3.7. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Offering (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Application (2021-2033)

13.3.8.3. Market Revenue and Forecast, by End User (2021-2033)

13.3.8.4. Market Revenue and Forecast, by Technology (2021-2033)

13.3.9. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Offering (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Application (2021-2033)

13.3.10.3. Market Revenue and Forecast, by End User (2021-2033)

13.3.10.4. Market Revenue and Forecast, by Technology (2021-2033)

13.3.10.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Offering (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Application (2021-2033)

13.3.11.3. Market Revenue and Forecast, by End User (2021-2033)

13.3.11.4. Market Revenue and Forecast, by Technology (2021-2033)

13.3.11.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Offering (2021-2033)

13.4.2. Market Revenue and Forecast, by Application (2021-2033)

13.4.3. Market Revenue and Forecast, by End User (2021-2033)

13.4.4. Market Revenue and Forecast, by Technology (2021-2033)

13.4.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Offering (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

13.4.6.3. Market Revenue and Forecast, by End User (2021-2033)

13.4.6.4. Market Revenue and Forecast, by Technology (2021-2033)

13.4.7. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Offering (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Application (2021-2033)

13.4.8.3. Market Revenue and Forecast, by End User (2021-2033)

13.4.8.4. Market Revenue and Forecast, by Technology (2021-2033)

13.4.9. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Offering (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Application (2021-2033)

13.4.10.3. Market Revenue and Forecast, by End User (2021-2033)

13.4.10.4. Market Revenue and Forecast, by Technology (2021-2033)

13.4.10.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Offering (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Application (2021-2033)

13.4.11.3. Market Revenue and Forecast, by End User (2021-2033)

13.4.11.4. Market Revenue and Forecast, by Technology (2021-2033)

13.4.11.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Offering (2021-2033)

13.5.2. Market Revenue and Forecast, by Application (2021-2033)

13.5.3. Market Revenue and Forecast, by End User (2021-2033)

13.5.4. Market Revenue and Forecast, by Technology (2021-2033)

13.5.5. Market Revenue and Forecast, by Functionality (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Offering (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Application (2021-2033)

13.5.6.3. Market Revenue and Forecast, by End User (2021-2033)

13.5.6.4. Market Revenue and Forecast, by Technology (2021-2033)

13.5.7. Market Revenue and Forecast, by Functionality (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Offering (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Application (2021-2033)

13.5.8.3. Market Revenue and Forecast, by End User (2021-2033)

13.5.8.4. Market Revenue and Forecast, by Technology (2021-2033)

13.5.8.5. Market Revenue and Forecast, by Functionality (2021-2033)

Chapter 14. Company Profiles

14.1. IBM

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. NVIDIA Corporation

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Benevolent AI

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Verge Genomics

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. MolecularMatch, Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. SOPHiA GENETICS

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. PrecisionLife Ltd.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Lifebit

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. FDNA, Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Empiric Logic

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client